NDA 020560 · Organon
Fosamax
Alendronate Sodium · Oral
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Feb 3, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1995
Sep 29, 1995
Approved uses
13
Original approval plus efficacy supplements
Registered trials
181
59 Phase 3, 7 recruiting
FAERS reports
83,679
66,990 serious, 10,774 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 12, 2026.
FOSAMAX is a bisphosphonate indicated for: Treatment and prevention of osteoporosis in postmenopausal women ( 1.1 , 1.2 ) Treatment to increase bone mass in men with osteoporosis ( 1.3 ) Treatment of glucocorticoid-induced osteoporosis ( 1.4 ) Treatment of Paget's disease of bone ( 1.5 ) Limitations of use : Optimal duration of use has not been determined. For patients at low-risk for fracture, consider drug discontinuation after 3 to 5 years of use. ( 1.6 ) 1.1 Treatment of Osteoporosis in Postmenopausal Women FOSAMAX ® is indicated for the treatment of osteoporosis in postmenopausal women. In postmenopausal women, FOSAMAX increases bone mass and reduces the incidence of fractures, including those of the hip and spine (vertebral compression fractures). [See Clinical Studies (14.1) .] 1.2 Prevention of Osteoporosis in Postmenopausal Women FOSAMAX is indicated for the prevention of postmenopausal osteoporosis [see Clinical Studies (14.2) ] . 1.3 Treatment to Increase Bone Mass in Men with Osteoporosis FOSAMAX is indicated for treatment to increase bone mass in men with osteoporosis [see Clinical Studies (14.3) ] . 1.4 Treatment of Glucocorticoid-Induced Osteoporosis FOSAMAX is indicated for the treatment of glucocorticoid-induced osteoporosis in men and women receiving glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and who have low bone mineral density [see Clinical Studies (14.4) ] . 1.5 Treatment of Paget's Disease of Bone FOSAMAX is indicated for the treatment of Paget's disease of bone in men and women. Treatment is indicated in patients with Paget's disease of bone who have alkaline phosphatase at least two times the upper limit of normal, or those who are symptomatic, or those at risk for future complications from their disease....
Mechanism: Animal studies have indicated the following mode of action. At the cellular level, alendronate shows preferential localization to sites of bone resorption, specifically under osteoclasts. The osteoclasts adhere normally to the bone surface but lack the ruffled border that is indicative of active resorption. Alendronate does not interfere with osteoclast recruitment or attachment, but it does inhibit osteoclast activity. Studies in mice on the localization of radioactive [ 3 H]alendronate in bone showed about 10-fold higher uptake on osteoclast surfaces than on osteoblast surfaces. Bones...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 21, 2005 Supplement 38 · Efficacy · priority review LetterLabel
- Apr 16, 2004 Supplement 41 · Efficacy ReviewLabelLetter
- Jan 31, 2001 Supplement 25 · Efficacy LetterLabel
- Oct 20, 2000 Supplement 22 · Efficacy LetterLabel
- Oct 20, 2000 Supplement 21 · Efficacy LabelLetter
- Sep 29, 2000 Supplement 23 · Efficacy Letter
- Nov 24, 1999 Supplement 18 · Efficacy ReviewLetter
- Nov 24, 1999 Supplement 15 · Efficacy ReviewLetter
- Jun 16, 1999 Supplement 12 · Efficacy ReviewLetterLabel
- Jun 8, 1999 Supplement 13 · Efficacy LabelReviewLetter
- Apr 25, 1997 Supplement 3 · Efficacy Review
- Apr 25, 1997 Supplement 6 · Efficacy Review
- Sep 29, 1995 Original approval · Type 1 - New Molecular Entity · priority review Pediatric Written RequestPediatric Reissue Amendment 1Pediatric Medical Review
5 products under this application
- FOSAMAX · ALENDRONATE SODIUM EQ 70MG BASE · TABLET, ORAL · Prescription · TE AB
- FOSAMAX · ALENDRONATE SODIUM EQ 5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued
- FOSAMAX · ALENDRONATE SODIUM EQ 10MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued
- FOSAMAX · ALENDRONATE SODIUM EQ 35MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued
- FOSAMAX · ALENDRONATE SODIUM EQ 40MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Alendronate" as an intervention, any sponsor and status, largest first.
- Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With OsteoporosisPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT01631214 · 4,093 participants · Start May 4, 2012 · Primary completion Feb 27, 2017
Drug: Romosozumab; Alendronate and 2 more · For: Postmenopausal Women With Osteoporosis
Sites: Birmingham, Alabama; Peoria, Arizona; Phoenix, Arizona · 316 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT02604836 · 1,711 participants · Start Jun 2004 · Primary completion Apr 2006
Drug: Ibandronate · For: Postmenopausal Osteoporosis
Sites: Birmingham, Alabama; Columbiana, Alabama; Huntsville, Alabama · 142 sites in all
- A Clinical Study on the Effect of Discontinuing Alendronate in Postmenopausal Women With Osteoporosis After a Treatment Period Without FracturesPivotal-lookingRecruiting
Odense University HospitalAcademic, hospital or other
NCT06864130 · 1,400 participants (planned) · Start Feb 21, 2025 · Primary completion Mar 1, 2029
Drug: Alendronate 70mg weekly · For: Osteoporosis in Post-menopausal Women
Sites: Aalborg, Denmark; Copenhagen, Denmark; Esbjerg, Denmark · 8 sites in all
- Denosumab Fracture Intervention Randomized Placebo Controlled Trial in Japanese Patients With OsteoporosisPivotal-lookingCompleted
Daiichi Sankyo Co., Ltd.Daiichi Sankyo (DSNKY)
NCT00680953 · 1,262 participants · Start May 2008 · Primary completion Jun 2012
Drug: Denosumab; Placebo and 1 more · For: Osteoporosis
Sites: Fukuoka, Japan; Osaka, Japan; Sapporo, Japan · 4 sites in all
- A Randomized, Double-Blind Study to Compare the Efficacy of Treatment With Denosumab Versus Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density.Pivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT00330460 · 1,189 participants · Start May 2006 · Primary completion Nov 2007
Drug: Alendronate; Denosumab · For: Osteoporosis; Osteopenia
- Twenty-Four Month Extension Study of BA058-05-003 (Abaloparatide) in Participants With OsteoporosisPivotal-lookingCompleted
Radius Health, Inc.Industry
NCT01657162 · 1,139 participants · Start Nov 20, 2012 · Primary completion Oct 3, 2016
Drug: Alendronate · For: Postmenopausal Osteoporosis
Sites: Lakewood, Colorado; Hialeah, Florida; Bethesda, Maryland · 25 sites in all
- FLEX - Long-term Extension of FIT (Fracture Intervention Trial)(0217-051)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00398931 · 1,099 participants · Start Feb 1998 · Primary completion Oct 2003
Drug: MK0217, alendronate sodium / Duration of Treatment : 5 Years; Comparator : placebo (unspecified) /Duration of Treatment : 5 Years · For: Osteoporosis, Postmenopausal
- A Study to Evaluate and Compare Alendronate and Risedronate on Bone Mineral Density in Women With Postmenopausal Osteoporosis (MK-0217-211)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00092014 · 1,053 participants · Start Sep 1, 2002 · Primary completion Apr 1, 2004
Drug: Alendronate; Risedronate 35 mg and 2 more · For: Postmenopausal Osteoporosis
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- pain13,040
- fatigue12,258
- drug ineffective11,759
- femur fracture11,065
- arthralgia10,508
- rheumatoid arthritis10,154
- alopecia9,989
- abdominal discomfort9,939
- systemic lupus erythematosus9,388
- pemphigus9,118
- rash8,790
- glossodynia8,478
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 3,094 |
| 2005 | 3,438 |
| 2006 | 3,302 |
| 2007 | 3,751 |
| 2008 | 3,254 |
| 2009 | 3,260 |
| 2010 | 4,088 |
| 2011 | 4,620 |
| 2012 | 8,031 |
| 2013 | 3,906 |
| 2014 | 2,882 |
| 2015 | 2,893 |
| 2016 | 2,519 |
| 2017 | 2,434 |
| 2018 | 2,492 |
| 2019 | 2,771 |
| 2020 | 3,385 |
| 2021 | 4,878 |
| 2022 | 4,270 |
| 2023 | 2,985 |
| 2024 | 4,689 |
| 2025 | 4,240 |
| 2026 | 2,496 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Fosamax (Alendronate Sodium)
2024 spending
$446K
Beneficiaries
459
1,437 claims
Per beneficiary
$971
$34.22 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $131,892 |
| 2022 | $477,192 |
| 2023 | $449,342 |
| 2024 | $445,614 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
Saag KG, Petersen J, Brandi ML, et al. · N Engl J Med 2017 · Clinical Trial, Phase III, Comparative Study
- Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.
Ayers C, Kansagara D, Lazur B, et al. · Ann Intern Med 2023 · Systematic Review, Network Meta-Analysis
- The Clinical Effectiveness of Denosumab (Prolia®) for the Treatment of Osteoporosis in Postmenopausal Women, Compared to Bisphosphonates, Selective Estrogen Receptor Modulators (SERM), and Placebo: A Systematic Review and Network Meta-Analysis.
Moshi MR, Nicolopoulos K, Stringer D, et al. · Calcif Tissue Int 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- The Efficacy and Safety of Medical and Surgical Therapy in Patients With Primary Hyperparathyroidism: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Ye Z, Silverberg SJ, Sreekanta A, et al. · J Bone Miner Res 2022 · Meta-Analysis, Systematic Review
- Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.
Black DM, Cummings SR, Karpf DB, et al. · Lancet 1996 · Clinical Trial, Randomized Controlled Trial
- Alendronate modulates cytokine responses in healthy young individuals after BCG vaccination.
Bulut O, Kilic G, Debisarun PA, et al. · Immunol Lett 2024 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Organon
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.